Glutamine

Glutamine

SCHEMBL4067710

NC(=O)CCC(N)C(=O)O.O=S(=O)(O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.83
KMT2A Q03164 2/20 0.83
ALOX15 P16050 1/20 0.83
BLM P54132 1/20 0.83
GSR P00390 2/20 0.58
CYP1A2 P05177 2/20 0.58
GRM8 O00222 2/20 0.58
GRM6 O15303 2/20 0.58
GRM7 Q14831 2/20 0.58
GRM4 Q14833 2/20 0.58
GRIN2D O15399 1/20 0.58
GRIN3B O60391 1/20 0.58
GRIK1 P39086 1/20 0.58
GRM5 P41594 1/20 0.58
GRIA1 P42261 1/20 0.58
GRIA2 P42262 1/20 0.58
GRIA3 P42263 1/20 0.58
SLC1A3 P43003 1/20 0.58
SLC1A2 P43004 1/20 0.58
SLC1A1 P43005 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL4067712 1.00 PMP22 (0.83) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL29087468 0.98 PMP22 (0.79) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL28103475 0.98 PMP22 (0.79) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL29087469 0.98 PMP22 (0.79) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL28103476 0.98 PMP22 (0.79) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL28099453 0.92 PMP22 (0.76) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL31412696 0.92 PMP22 (0.76) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL411575 0.91 KMT2A (1.00) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL5580393 0.91 KMT2A (1.00) PMP22KMT2AALOX15BLMGSR
Glutamine SCHEMBL994966 0.91 KMT2A (1.00) PMP22KMT2AALOX15BLMGSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10813305-B2 Regeneration and transformation of Cosmos Bipinnatus plantlets NOVIN GITI GENE R&D CENTER (N.G.G.) (IR) 2020-10-27 US claimed
US-20170231177-A1 REGENERATION AND TRANSFORMATION OF COSMOS BIPINNATUS PLANTLETS Novin Giti Gene R&D Center (N.G.G) (IR) 2017-08-17 US claimed
CN-107835852-B Controlled foam break up rate in hard surface cleaners 艺康美国股份有限公司 2024-02-23 CN disclosed
US-20210393497-A1 ANTIMICROBIAL COMPOSITIONS CONTAINING SOLVENTS INCLUDING A C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM VIROX TECHNOLOGIES INC. (CA) 2021-12-23 US disclosed
US-20210386066-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM CONTAINING ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING SAME VIROX TECHNOLOGIES INC. (CA) 2021-12-16 US disclosed
US-20210315207-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM-CONTAINING ANTIMICROBIAL COMPOSITIONS AND USES THEREOF VIROX TECHNOLOGIES INC. (CA) 2021-10-14 US disclosed
US-20210307327-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM-CONTAINING AN ANTIMICROBIAL COMPOSITIONS AND USES THEREOF VIROX TECHNOLOGIES INC. (CA) 2021-10-07 US disclosed
CN-113260419-A Indazolyl cyanoethylamino compounds, compositions thereof, methods of making the same, and methods of using the same 勃林格殷格翰动物保健美国公司 2021-08-13 CN disclosed
EP-2203222-B1 INJECTABLE DERMATOLOGICAL COMPOSITION FOR TREATMENT OF WRINKLES ITALFARMACIA S R L (IT) 2021-08-04 EP disclosed
CN-108055825-B Extended release injectable formulations comprising isoxazoline active agents, methods and uses thereof 勃林格殷格翰动物保健美国公司 2021-03-30 CN disclosed
US-10813305-B2 Regeneration and transformation of Cosmos Bipinnatus plantlets NOVIN GITI GENE R&D CENTER (N.G.G.) (IR) 2020-10-27 US disclosed
CN-1694958-A Gene expression system based on codon translation efficiency UNIV QUEENSLAND (AU) 2005-11-09 CN disclosed
CN-1643135-A Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same STEMRON INC (US) 2005-07-20 CN disclosed
CN-1197587-C Application of position-N desulfurizing heparin in preventing and treating inflammation SHANGHAI INST OF CYTOBIOLOGY C (CN) 2005-04-20 CN disclosed
CN-1327795-A Application of position-N desulfurizing heparin in preventing and treating inflammation SHANGHAI INST OF CYTOBIOLOGY C (CN) 2001-12-26 CN disclosed
CN-1325441-A Modified exosomes and uses INST NAT SANTE ET DELA RECH ME (FR) 2001-12-05 CN disclosed
CN-1178554-A chemically modified interperon AMGEN INC (US) 1998-04-08 CN disclosed
EP-0658188-A4 LIQUID OR GEL DETERGENT COMPOSITIONS CONTAINING CALCIUM AND STABILIZING AGENT THEREOF. PROCTER & GAMBLE (US) 1995-08-09 EP disclosed
EP-0658188-A1 LIQUID OR GEL DETERGENT COMPOSITIONS CONTAINING CALCIUM AND STABILIZING AGENT THEREOF THE PROCTER & GAMBLE COMPANY (US) 1995-06-21 EP disclosed
WO-1994005758-A1 LIQUID OR GEL DETERGENT COMPOSITIONS CONTAINING CALCIUM AND STABILIZING AGENT THEREOF THE PROCTER & GAMBLE COMPANY (US) 1994-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315207-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM-CONTAINING ANTIMICROBIAL COMPOSITIONS AND USES THEREOF C5, C9, C3AR1 PMP22 939/4885KMT2A 2963/4885ALOX15 14/4885
US-20210393497-A1 ANTIMICROBIAL COMPOSITIONS CONTAINING SOLVENTS INCLUDING A C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM EBP, C5, CPS1 PMP22 1894/4885KMT2A 4289/4885ALOX15 59/4885
US-20210307327-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM-CONTAINING AN ANTIMICROBIAL COMPOSITIONS AND USES THEREOF C5, C9, C1S PMP22 381/4885KMT2A 3806/4885ALOX15 26/4885
US-20210386066-A1 C3-C5 N-ALKYL-GAMMA-BUTYROLACTAM CONTAINING ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING SAME C5, C1S, C9 PMP22 479/4885KMT2A 4078/4885ALOX15 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.